MESO
NASDAQMesoblast Limited
Price$13.79-0.08 (-0.58%)
02:00 PM07:45 PM
News · 26 weeks63-80%
2025-12-142026-06-07
Mix3490d
- Insider13(38%)
- SEC Filings11(32%)
- Other8(24%)
- Leadership1(3%)
- M&A1(3%)
Latest news
25 items- PRRegenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing ItIssued on behalf of Conexeu Sciences Inc.Companies mentioned: Conexeu Sciences Inc. (NASDAQ:CNXU), Integra LifeSciences Holdings Corporation (NASDAQ:IART), Evolus, Inc. (NASDAQ:EOLS), Bioventus Inc. (NASDAQ:BVS), Mesoblast Limited (NASDAQ:MESO)KEY TAKEAWAYSA fresh Nasdaq debut. Conexeu Sciences Inc. (NASDAQ:CNXU) began trading on May 21, 2026, marking the public-market entry of a Reno-based regenerative tissue platform company targeting wound care, breast reconstruction, and aesthetic medicine — three of the largest unmet-need categories in healthcare today.One platform, multiple markets. Conexeu's proprietary CXU™ extracellular matrix platform is designed to scale across multiple addressabl
- SECSEC Form 6-K filed by Mesoblast Limited6-K - MESOBLAST LTD (0001345099) (Filer)
- PRMesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 MillionAchieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Activity Report for Quarter Ended March 31, 2026 (Appendix 4C) NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the third fiscal quarter ended March 31, 2026. "We've had a busy and exciting March quarter marked by a series of major achievements. Ryoncil® revenues are now approaching US$100 million since last year's launch, we have substantially improved our net operating cash spend, our pivotal trial in inflammatory back pain has succes
- INSIDERNew insider Cobley Lynette Elizabeth claimed ownership of 63,000 units of Ordinary Shares (SEC Form 3)3 - MESOBLAST LTD (0001345099) (Issuer)
- SECSEC Form 6-K filed by Mesoblast Limited6-K - MESOBLAST LTD (0001345099) (Filer)
- PRMesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back PainNEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its pivotal Phase 3 clinical trial evaluating rexlemestrocel-L for the treatment of chronic low back pain (CLBP) associated with degenerative disc disease has achieved its patient recruitment target. This marks a significant milestone in Mesoblast's plans for commercialization of rexlemestrocel-L, its proprietary allogeneic stromal cell therapy targeting inflammatory processes underlying disc degeneration. The placebo-controlled study (MSB-DR004) will follow at least 300 patients randomized to a single intra-
- SECSEC Form 6-K filed by Mesoblast Limited6-K - MESOBLAST LTD (0001345099) (Filer)
- SECSEC Form 6-K filed by Mesoblast Limited6-K - MESOBLAST LTD (0001345099) (Filer)
- PRMesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell ProductsNEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has acquired an exclusive worldwide license to a patented chimeric antigen receptor (CAR) technology platform for precision-enhanced augmentation of therapeutic mesenchymal lineage stromal cell (MSC) products. Mesoblast plans to incorporate the engineered CARs to further boost effectiveness of Mesoblast's products, with the goal of enhancing the target specificity and augmenting inherent properties of immunomodulation and tissue regeneration. Mesoblast's MSC technology platforms, including the first and on
- INSIDERSEC Form 4 filed by George Gregory4 - MESOBLAST LTD (0001345099) (Issuer)
- INSIDERSEC Form 4 filed by George Gregory4 - MESOBLAST LTD (0001345099) (Issuer)
- PRMesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTIONWorking with Parent Project Muscular Dystrophy and the Duchenne Registry on patient identification and trial awareness efforts ~15,000 children are living with DMD in the U.S. NEW YORK, April 10, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance to directly proceed for a registrational clinical trial evaluating Ryoncil® (remestemcel-L-rknd) in Duchenne muscular dystrophy (DMD), which affects approximately 15,000 children in the U.S.1 Ryoncil® is the first mesenchymal str
- PRMesoblast R&D Day Features Significant Commercial Progress & Platform InnovationMesoblast outlines commercial strategy to double net revenues as Ryoncil® approaches US$100M net revenue milestone since launch last year Showcases transformative blockbuster products for inflammatory back pain and heart failure Announces close of enrollment for Phase 3 trial for CLBP at the end of this month Highlights label extension strategy for Ryoncil® in adult and pediatric rare diseases: - Adult SR-aGvHD trial cleared by central institutional review board (IRB), first sites to be activated this quarter - FDA cleared IND to directly proceed to registrational trial for approval of Ryoncil® in children with Duchenne muscular dystrophy (DMD) Announces acquisition of a patented
- SECSEC Form 6-K filed by Mesoblast Limited6-K - MESOBLAST LTD (0001345099) (Filer)
- SECSEC Form 6-K filed by Mesoblast Limited6-K - MESOBLAST LTD (0001345099) (Filer)
- SECSEC Form 6-K filed by Mesoblast Limited6-K - MESOBLAST LTD (0001345099) (Filer)
- SECSEC Form 6-K filed by Mesoblast Limited6-K - MESOBLAST LTD (0001345099) (Filer)
- PRMesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular DystrophyPartnering with Parent Project Muscular Dystrophy to ensure timely access to the trial for eligible patients ~15,000 children are living with DMD in the U.S. NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance to directly proceed for a registrational clinical trial evaluating Ryoncil® (remestemcel-L-rknd) in Duchenne muscular dystrophy (DMD), which affects approximately 15,000 children in the U.S.1 Ryoncil® is the first mesenchymal stromal cell (MSC) pro
- PRRyoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March QuarterStrong growth in February/March following January seasonality Net revenue approaches US$100M since launch NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced Ryoncil® (remestemcel-L-rknd) net sales were US$30.3 million for the quarter ended March 31, 2026.1 Strong sales in February and March offset holiday seasonality in January. Revenue generated during this first year of Ryoncil® launch approaches US$100 million. Ryoncil® revenue strengthens Mesoblast's balance sheet and supports label extension and late-stage blockbuster programs. Ryoncil® is the first mesench
- INSIDERSEC Form 3 filed by new insider Burns William Murray3 - MESOBLAST LTD (0001345099) (Issuer)
- INSIDERSEC Form 3 filed by new insider Itescu Silviu3 - MESOBLAST LTD (0001345099) (Issuer)
- INSIDERSEC Form 3 filed by new insider Itescu Silviu3 - MESOBLAST LTD (0001345099) (Issuer)
- INSIDERSEC Form 3 filed by new insider George Gregory3 - MESOBLAST LTD (0001345099) (Issuer)
- SECSEC Form 6-K filed by Mesoblast Limited6-K - MESOBLAST LTD (0001345099) (Filer)
- INSIDERSEC Form 3 filed by new insider Krause Philip R.3 - MESOBLAST LTD (0001345099) (Issuer)
MESO FAQ
7 questionsWhat does Mesoblast Limited do?
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic...Where does MESO stock trade?
Mesoblast Limited (MESO) is listed on NASDAQ.What sector and industry is MESO in?
Mesoblast Limited operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Mesoblast Limited go public?
Mesoblast Limited (MESO) completed its IPO in 2015.What are analysts saying about MESO?
Mesoblast Limited has had 8 recent analyst actions on file. The most recent action was from Jefferies: Buy on 2025-11-25. Recent price targets range from $1100.00 to $1200.00.What companies are similar to MESO?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare MESO side-by-side with any of them on Quantisnow.How can I track MESO on Quantisnow?
Quantisnow aggregates Mesoblast Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MESO to receive live email and push alerts on every new disclosure.